Clinical Trial Search

Primary: Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Criteria Version 1.0 — 13.5; 13.5 Percentage of participants

Primary: Number of Participants With Presence of Fluorescence of cT1 RCC in Partial Nephrectomy Specimens — 10 Participants

Primary: Progression Free Survival (PFS) of Carfilzomib Therapy in Participants With Refractory Or Intolerant to Prior Therapy — 1.8 Months

Primary: Sensitivity and Specificity of 124I-cG250 PET/CT Versus Diagnostic CT. — 0.76; 0.86; 0.86; 0.47 Proportion of participants — p=0.023

Primary: Number of Participants With 18F-DCFPyL PET/CT Detected Sites of Metastatic Renal Cell Carcinoma (RCC) — 34 Participants

Primary: Duration of Sunitinib and Pazopanib Treatment in Participants — 171; 114.5 days

Primary: Response Rate — 8 Participants

Primary: Percentage of Participants With Response — 0; 15; 65; 10 percentage of participants

Primary: PFS (Progression-Free Survival) — 27.71 Weeks

Primary: Anti-tumor Activity as Measured by Median Progression Free Survival Time — 5.6; 8.3 Months — p=0.157

Primary: Progression-free Survival — 1.7 months

Primary: Biomarkers in Blood and Archived Tissue Samples, and Their Correlation With Clinical Activity in Subjects With Advanced Renal Cell Cancer Treated With Tivozanib.

Primary: Best Overall Response Rate — 33 percentage of participants

Primary: To Evaluate Efficacy of RAD001 as Monotherapy for the Treatment of Papillary Renal Cancer. Efficacy is Defined as the Percentage of Patients Progression-free at 6…

Primary: Best Response by RECIST v1.0 — 0; 1; 0; 1 Participants

Primary: Objective Response Rate (RECIST Version 1.1) — 0; 0; 3; 8 Participants

Primary: Progression Free Survival (PFS) — 11 months

Primary: Number of Patients in Which the Treatment Was Tolerable — 5 Participants

Primary: Pharmacokinetics Measured as Area Under Curve (AUC[0-12h]) — 35.5; 5.7 mg*hour/Liter

Primary: Overall Response Rate (ORR) in VHL Disease-Associated ccRCC Tumors — 0.0 Percentage of Participants

Primary: Response Rate by Solid Tumor Response Criteria (RECIST) — 16 Percentage of Participants

Primary: Number of Participants With Change in Radiologist's Lesion Evaluation — 0; 11; 0; 1 Participants

Primary: Number of Patients With Treatment-emergent Adverse Events — 3; 3; 6; 3 Participants

Primary: Disease-free Survival (DFS) With Pazopanib 600 mg Daily Initial Dose vs. Placebo — NA; NA months — p=0.1649

Primary: Overall Response Rate — 27 percentage of patients

Primary: Progression-free Survival — 9.2; 4.2 months — p=.0000001

Primary: Progression-Free Survival (PFS) - Percentage of Participants Estimated to be Progression Free at 12 and 24 Months — 58.2; 28.9 percentage of participants

Primary: Metabolic Response — 5 participants

Primary: Overall Survival (OS) — 7.3; 10.9; 8.4 months — p=0.0252

Primary: Progression Free Survival (PFS) — 2.63; 4.11; 4.17 Months